Genetic Technology Alert. Promising Gene Therapy for Beta Thalassemia Patients; Nanoparticle Gene Therapy for Brain Tumors; Genetic Predictor Protein for Gestational Diabetes

USD 250

* Required Fields

USD 250

PAY BY INVOICE

Be the first to review this product

This issue profiles a promising gene therapy for beta thalassemia patients, a nanoparticle gene therapy for brain tumors, and a genetic predictor protein for gestational diabetes.

Table of Contents

Genetic Technology Alert. Promising Gene Therapy for Beta Thalassemia Patients; Nanoparticle Gene Therapy for Brain Tumors; Genetic Predictor Protein for Gestational DiabetesIn This Issue1. PROMISING GENE THERAPY FOR BETA THALASSEMIA PATIENTS2. NANOPARTICLE GENE THERAPY FOR BRAIN TUMORS3. GENETIC PREDICTOR PROTEIN FOR GESTATIONAL DIABETES4. RECENT PATENTS IN GENE THERAPY IN NORTH AMERICA




Related Research

Release Date : 19-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Release Date : 12-May-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.